NEWS HIGHLIGHTS
Published Studies Related to Timolol (Timolol Ophthalmic)
Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus
bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or
ocular hypertension: a 12-week randomised controlled trial. [2014] hypertension... CONCLUSIONS: Bimatoprost/timolol PF demonstrated non-inferiority and equivalence
Effect of timolol on refractive outcomes in eyes with myopic regression after
laser in situ keratomileusis: a prospective randomized clinical trial. [2012] (length 4 to 8) was used for treatment allocation... CONCLUSIONS: Timolol application is effective for the treatment of myopic
Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol. [2011.10] PURPOSE: To evaluate bimatoprost versus latanoprost and timolol fixed combination (LTFC) over the 24-hour diurnal curve in patients who switched from timolol... CONCLUSIONS: The LTFC and bimatoprost therapies were equally effective in maintaining IOP at lower levels during the 24-hour period in patients who switched from timolol therapy. Adverse events were more frequent with bimatoprost therapy.
Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. [2011.09] PURPOSE: The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension... CONCLUSION: Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy. No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. [2011.08.19] BACKGROUND: A noninferiority trial was conducted to evaluate the efficacy of a single evening dose of fixed-combination latanoprost 50 mug/mL and timolol 0.5 mg/mL (Xalacom(R); LTFC), in Chinese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who were insufficiently controlled on beta-blocker monotherapy or beta-blocker-based dual therapy... CONCLUSIONS: A single evening dose of LTFC was at least as effective as the unfixed combination of latanoprost in the PM and timolol in the AM in reducing IOP in Chinese subjects with POAG or OH whose IOP was insufficiently reduced with beta-blocker monotherapy or beta-blocker-based dual therapy. LTFC is an effective and well tolerated once-daily treatment for POAG and OH.
Clinical Trials Related to Timolol (Timolol Ophthalmic)
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial) [Withdrawn]
The purpose of this study is to determine whether Timolol 0. 5% Gel Forming Solution is safe
and effective in promoting wound healing of infantile ulcerated hemangiomas compared with
standard conservative management with topical antibiotic.
Topical Timolol Benefit in Venous Ulcers [Not yet recruiting]
Background: Venous Leg ulcers are a frequent pathology in dermatology and complex in their
management. At the origin of high health costs and strong repercussions on quality of life
for patients, they require long management and may be subject to possible complications.
In spite of appropriate treatment, 50-60% of these ulcers are not healed at 24 weeks.
Purpose: Topical beta adrenergic antagonists have shown efficacy in wound healing. The
purpose of this study is to evaluate the efficacy and safety of treatment of chronic venous
ulcers with topical timolol.
24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG [Completed]
A crossover, randomized, single-masked study which compares the short-term (3 months)
24-hour IOP control and safety of travoprost/timolol fixed combination given once in the
evening, versus that of latanoprost/timolol fixed combination given once in the evening in
patients with exfoliative glaucoma. The primary objective of this trial is to compare the
quality of 24-hour IOP control after 3 months of chronic therapy with these two medications.
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5% [Withdrawn]
The purpose of this study is to evaluate the feasibility of rapid evaluation and
administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior
ischemic optic neuropathy. Secondary goals are to evaluate if such treatment reduces the
progression or improves recovery of patients who are randomly assigned to treatment versus
standard of care.
|